Item 7.01 Regulation FD Disclosure.

Prevail Therapeutics Inc. (the "Company") is providing a set of frequently asked questions and the Company's responses (the "Q&A") relating to the decision of the arbitrator in connection with the arbitration proceeding between Dr. Asa Abeliovich, the Company's Chief Executive Officer, and Alector, Inc. The Company was not a party to the proceeding. A copy of the Q&A is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



    Exhibit
    No.       Description

    99.1        Frequently Asked Questions Regarding Arbitration Decision.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses